Read more here:
Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
Author Archives: Fredricko
Tilray Medical Expands Commercial Footprint in Europe and Broadens Distribution Across the Czech Republic
Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
Mendus redeems the outstanding convertible bonds from Negma Group
Virbac : Declaration of the number of shares and voting rights 03/2023
Read the original here:
Virbac : Declaration of the number of shares and voting rights 03/2023
Ipsen S.A. publishes its 2022 Universal registration document
Read the original:
Ipsen S.A. publishes its 2022 Universal registration document
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
Originally posted here:
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
Societal CDMO Reports Inducement Grants for New Staff
Excerpt from:
Societal CDMO Reports Inducement Grants for New Staff
Lifecore Biomedical Announces Sale of Curation Foods’ O Olive Oil and Vinegar® Business
Tonix Pharmaceuticals Presents Data from its Vaccine Development Program at the World Vaccine Congress
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities
Originally posted here:
NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities
Covis Statement on FDA Decision to Withdraw Approval of Makena®
See the article here:
Covis Statement on FDA Decision to Withdraw Approval of Makena®
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MDxHealth Shareholder Transparency Declaration
Here is the original post:
MDxHealth Shareholder Transparency Declaration
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
Read the rest here:
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read the original here:
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)